Ill. Admin. Code tit. 77, § 661.210 - Blood Spot Reporting
Any medical care facility or health care provider submitting newborn screening specimens to the Illinois Department of Public Health Laboratory shall comply with all requirements of this Part, and shall notify the Department immediately whenever further testing on a newborn that was performed by the medical care facility or another outside laboratory indicates that:
a) phenylalanine levels are
abnormal;
b) T4 determinations are
abnormal or TSH determinations are abnormal;
c) total galactose or galactose-1-phosphate
uridyl transferase determinations are abnormal;
d) 17-hydroxyprogesterone determinations are
abnormal;
e) biotinidase enzyme
determinations are abnormal;
f)
abnormal hemoglobin patterns are identified;
g) abnormal amino acid or acylcarnitine
patterns have been identified;
h)
abnormal determinations that may indicate cystic fibrosis have been
identified;
i) abnormal
determinations that may indicate a lysosomal storage disorder have been
identified;
j) abnormal
determinations that may indicate severe combined immunodeficiency or T cell
lymphopenia have been identified;
k) abnormal determinations that may indicate
adrenoleukodystrophy have been identified; or
l) abnormal determinations that may indicate
spinal muscular atrophy have been identified.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.